Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01762696
Other study ID # 1R34DA030535-01A1
Secondary ID
Status Completed
Phase N/A
First received January 4, 2013
Last updated December 9, 2016
Start date May 2013
Est. completion date May 2016

Study information

Verified date December 2016
Source Boston Children’s Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Data and Safety Monitoring BoardUnited States: Federal GovernmentUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to further develop and test the Momentary Self-Monitoring and Feedback + Motivational Enhancement Therapy (MOMENT) intervention, a real-time, contextual intervention to reduce marijuana use among primary care patients.


Description:

This study proposes a pilot randomized trial to further develop and test the Momentary Self-Monitoring and Feedback + Motivational Enhancement Therapy (MOMENT) intervention, a real-time, contextual intervention to reduce marijuana use over three months in 15-to-24-year-old primary care patients who use frequently. We will randomize youth to one of two arms (goal 30 per arm completing 3-month follow-up): 1) MOMENT (MET + momentary self-monitoring + context-dependent feedback), or 2) MET-only. The two study arms will permit evaluation of the contributions of the self-monitoring and feedback components of the intervention above-and-beyond the MET and directly test the influence of the intervention on the link between momentary context and marijuana-related outcomes.

The specific aims of the study are

Specific Aim 1: Continued Feasibility Evaluation. In our preliminary work, we demonstrated that 1) youth perceive MOMENT to be easy to understand, comfortable, motivating, and helpful in reducing their marijuana use, 2) we can recruit 4 participants/month (minimum rate for the proposed study), and 3) we can successfully implement a MOMENT intervention study in the proposed recruitment sites. Based on this work, we have identified additional areas of feasibility on which to focus in the proposed study. Specifically, we aim to achieve:

1a. A signal response rate of at least 70% during each of three periods of momentary data collection - baseline, intervention, and 3-month follow-up.

1b. A diary response rate of at least 70% during each momentary data collection period

1. c. A retention rate of at least 80% of participants at the 3-month follow-up.

Specific Aim 2. Early-Stage Efficacy Exploration. Our preliminary work showed that both momentary and individual-level outcomes improved from baseline to three months post-intervention. The primary momentary outcomes are desire to use marijuana when in a triggering context and likelihood of use following exposure to a triggering context. The primary individual-level outcomes are number of use events/week, 30-day percent of days abstinent, dose/use event, and measures of motivation (importance of, readiness for, and confidence about reducing use). Based on the preliminary findings, we will explore these early-stage efficacy questions:

2. a. Will improvements in momentary outcomes be observed with MOMENT, but not MET-only?

(1) The association between exposure to self-identified trigger contexts and momentary desire to use marijuana will be attenuated at three months, compared to pre-intervention.

(2) The likelihood of marijuana use following exposure to a trigger context will be reduced at three months.

2b. Will improvements in individual-level outcomes be greater with MOMENT vs. MET-only?

1. The reduction in marijuana use frequency (events/week and 30-day percent of days abstinent) and dose (per use event) will be greater at three months.

2. The increase in motivation to reduce or discontinue use will be greater at three months.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender Both
Age group 15 Years to 24 Years
Eligibility Inclusion Criteria:

- Male or female between the ages of 15-24 years

- Patient of the Boston Children's Hospital Adolescent/Young Adult Medicine Clinic or Martha Elliot Health Center Adolescent Clinic

- Ability to read and understand English

Exclusion Criteria:

- Medically or emotionally unstable, intoxicated or "high,", or otherwise unable to give consent at the time of their appointment

- Have previously participated in this study

- Does not meet the above inclusion criteria

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
MET
Motivational Enhancement Therapy only
MOMENT
The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana

Locations

Country Name City State
United States Boston Children's Hospital Adolescent/Young Adult Medical Clinic Boston Massachusetts
United States Martha Eliot Health Center Adolescent Clinic Jamaica Plain Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Boston Children’s Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Marijuana desire Desire to use marijuana when in top-3 trigger context 3 months No
Primary Marijuana use following trigger exposure Marijuana use following exposure to top-3 trigger context 3 months No
Primary Frequency of marijuana use Marijuana use events/day 3 months No
Primary Percent days abstinent 30-day percent days abstinent from marijuana use 3 months No
Primary Motivation to reduce marijuana use Daily score on 3 scales - readiness to reduce marijuana use, importance of reducing use, and confidence in ability to reduce use 3 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT00158249 - Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals Phase 2
Completed NCT00842985 - Dronabinol Interactions in Humans N/A
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00227864 - A Brief Marijuana Intervention for Adolescent Women - 1 Phase 3
Completed NCT00218478 - Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1 Phase 1
Completed NCT00227903 - Therapeutic Substance Abuse Treatment in Pregnancy - 1 Phase 2
Completed NCT00249509 - Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals Phase 2
Completed NCT03717272 - Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects Phase 2
Completed NCT00142961 - Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Phase 2
Terminated NCT02102230 - CBT-I for Cannabis Use N/A
Completed NCT00580671 - Treatment for Adolescent Marijuana Abuse N/A
Completed NCT00360269 - Atomoxetine Treatment for ADHD and Marijuana Dependence Phase 2
Completed NCT00227916 - Motivational Interviews for Incarcerated Teens - 1 N/A
Completed NCT03154567 - Effects of Stress and Drug-cue Exposure (SCM) Phase 1
Active, not recruiting NCT05322941 - Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) Phase 2
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT03154580 - Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users Phase 1
Completed NCT00217971 - Dronabinol Treatment for Marijuana Addiction Phase 2
Completed NCT00142870 - Effectiveness of Bupropion in Treating Marijuana Dependent Individuals Phase 2